CurifyLabs
Develops 3D printing-based technology for medicine compounding, enabling more flexible preparation of customized pharmaceuticals.
Overview
CurifyLabs builds technology for 3D printing-based medicine compounding, applying additive manufacturing methods to the preparation of pharmaceuticals. Its offering is aimed at organizations involved in compounding medicines and personalized drug preparation. The company’s key differentiator is its use of 3D printing as the basis for compounding workflows, positioning it within advanced pharmaceutical manufacturing rather than core AI. CurifyLabs raised a $12 million Series A in July 2026 to expand its medicine compounding platform.
Funding History
Finland’s CurifyLabs raises €12 million to expand 3D printing-based medicine compounding
Frequently Asked Questions
- How much funding does AI Funding track for CurifyLabs?
- AI Funding tracks $14M for CurifyLabs across 1 funding round in this database.
- Who are CurifyLabs's investors?
- CurifyLabs's investors include Sandwater, HealthCap.
- What does CurifyLabs do?
- CurifyLabs builds technology for 3D printing-based medicine compounding, applying additive manufacturing methods to the preparation of pharmaceuticals. Its offering is aimed at organizations involved in compounding medicines and personalized drug preparation. The company’s key differentiator is its use of 3D printing as the basis for compounding workflows, positioning it within advanced pharmaceutical manufacturing rather than core AI. CurifyLabs raised a $12 million Series A in July 2026 to expand its medicine compounding platform.
- Where is CurifyLabs headquartered?
- CurifyLabs is headquartered in Helsinki, Finland.
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.